Cambium Announces Orphan Drug Designation for Dry Eye Indication
First Biologic to Receive Orphan Drug Status for Ocular Graft-Vs.-Host Disease Dry Eye ATLANTA, GA –Feb. 26, 2020 – Cambium Medical Technologies (Cambium), a clinical stage company developing novel processed platelets for therapeutic applications, announced today that the U.S. Food & Drug Administration (FDA) has granted the company orphan drug designation for its fibrinogen-depleted human ...
Read more